The prognostic and predictive value of serum CA19.9 in pancreatic cancer

Humphris, J.L. et al. (2012) The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Annals of Oncology, 23(7), pp. 1713-1722. (doi:10.1093/annonc/mdr561) (PMID:22241899) (PMCID:PMC3387824)

[img]
Preview
Text
80793.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial.

535kB

Abstract

<p>Background: Current staging methods for pancreatic cancer (PC) are inadequate, and biomarkers to aid clinical decision making are lacking. Despite the availability of the serum marker carbohydrate antigen 19.9 (CA19.9) for over two decades, its precise role in the management of PC is yet to be defined, and as a consequence, it is not widely used.</p> <p>Methods: We assessed the relationship between perioperative serum CA19.9 levels, survival and adjuvant chemotherapeutic responsiveness in a cohort of 260 patients who underwent operative resection for PC.</p> <p>Results By specifically assessing the subgroup of patients with detectable CA19.9, we identified potential utility at key clinical decision points. Low postoperative CA19.9 at 3 months (median survival 25.6 vs 14.8 months, P = 0.0052) and before adjuvant chemotherapy were independent prognostic factors. Patients with postoperative CA 19.9 levels >90 U/ml did not benefit from adjuvant chemotherapy (P = 0.7194) compared with those with a CA19.9 of ≤90 U/ml median 26.0 vs 16.7 months, P = 0.0108). Normalization of CA19.9 within 6 months of resection was also an independent favorable prognostic factor (median 29.9 vs 14.8 months, P = 0.0004) and normal perioperative CA19.9 levels identified a good prognostic group, which was associated with a 5-year survival of 42%.</p> <p>Conclusions: Perioperative serum CA19.9 measurements are informative in patients with detectable CA19.9 (defined by serum levels of of >5 U/ml) and have potential clinical utility in predicting outcome and response to adjuvant chemotherapy. Future clinical trials should prioritize incorporation of CA19.9 measurement at key decision points to prospectively validate these findings and facilitate implementation.</p>

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Biankin, Professor Andrew and Chang, Dr David
Authors: Humphris, J.L., Chang, D.K., Johns, A.L., Scarlett, C.J., Pajic, M., Jones, M.D., Colvin, E.K., Nagrial, A., Chin, V.T., Chantrill, L.A., Samra, J.S., Gill, A.J., Kench, J.G., Merrett, N.D., Das, A., Musgrove, E.A., Sutherland, R.L., and Biankin, A.V.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cancer Sciences
Journal Name:Annals of Oncology
Publisher:Oxford University Press
ISSN:0923-7534
ISSN (Online):1569-8041
Copyright Holders:Copyright © 2012 The Authors
First Published:First published in Annals of Oncology 23(7):1713-1722
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record